Lantheus Holdings, Inc. (NASDAQ: LNTH) has seen a recent variation in its stock price, drawing attention from market watchers. This update reviews the company profile, trading information, and key financial metrics to provide investors with a concise overview.
Company Overview
Lantheus Holdings, Inc., founded in 1956 and headquartered in North Billerica, Massachusetts, develops, manufactures, and commercializes diagnostic and therapeutic products for clinicians worldwide. Its portfolio covers products used in cardiovascular imaging, cancer diagnosis, and other disease management including DEFINITY, TechneLite, Xenon-133, Neurolite, Cardiolite, Thallium-201, Gallium-67, and PYLARIFY. The company also pursues innovation through product development such as flurpiridaz F 18, PYLARIFY AI, and various targeted therapies.
Clients include hospitals, radio pharmacies, integrated delivery networks, and clinics. Partnerships with global firms such as Bayer AG, GE Healthcare, and FUJIFILM enhance its market reach and technological capabilities.
Stock Performance
As of the latest session, LNTH trades at USD 56.7074, marking a decrease of 0.6226 or approximately -1.08599% from the previous day’s close. This reflects short-term market sentiment and may be tied to broader sector movements or recent operational announcements.
The 52-week range of the stock spans from 47.25 to 118.21, indicating significant volatility over the past year. Investors may view this spread as both opportunity and risk, depending on their strategic approach.
Trading volume stood at 394,306, substantially below the average volume of 1,767,993. Lower-than-average volume can suggest a temporary quiet period or market caution; it also influences liquidity considerations for institutional investors.
Market Position and Sector
Lantheus operates in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector. This niche focuses on specialized treatments and diagnostics, often requiring deep regulatory knowledge and commitment to innovation.
With a market capitalization of approximately USD 3.86 billion, the company holds a solid position among its peers. Market capitalization reflects investor valuation based on outstanding shares and can influence analyst coverage and capital market access.
Governance and Leadership
Chief Executive Officer Brian A. Markison leads Lantheus. His role involves steering the company in strategy execution, operational efficiency, and sustaining partnerships with pharmaceutical and biotech leaders. Leadership stability is a factor in investor confidence, especially in regulated industries such as healthcare.
Key Financial Data
Price
At USD 56.7074, the stock is trading closer to the lower bound of its yearly range. This may appeal to value-focused investors seeking entry points.
Market Capitalization
The USD 3.86 billion market cap situates Lantheus in the mid-cap range, often balancing growth potential with operational maturity.
Dividends
Lantheus has a last dividend payout of 0, indicating it currently does not reward shareholders with cash dividends, possibly allocating capital towards research, development, or acquisitions.
Range
The wide 52-week range shows exposure to market swings, highlighting the importance of monitoring industry trends and company announcements.
Trading Volume
The current daily trading volume is below the average, potentially signaling reduced liquidity in the short term.
Identifiers and Exchange
LNTH is listed on the NASDAQ Global Market. International Securities Identification Number (ISIN) is US5165441032 and CUSIP is 516544103. The company CIK is 0001521036. These identifiers are crucial for precise trading and settlement operations across markets.
FAQ
- Does Lantheus Holdings, Inc. pay dividends? Currently, the last dividend was 0, so no cash dividends are paid.
- Where is Lantheus listed? The company is traded on the NASDAQ Global Market under the symbol LNTH.
- How many employees does Lantheus have? The company employs 808 full-time staff.
- What is the market capitalization? Approximately USD 3.86 billion.
- What is the 52-week price range? Between USD 47.25 and USD 118.21.
Conclusion
Lantheus Holdings, Inc. continues to maintain its role in the specialized drug manufacturing segment with strong diagnostic and therapeutic offerings. Current stock trends show moderate downward movement, with volume under average levels. Investors may factor these indicators with the company’s product pipeline and leadership stability when considering positions.
Disclaimer
This article is for informational purposes only. It is not financial advice. Investors should conduct their own research or consult a qualified advisor before making investment decisions.
Official Announcement
For full information about the company, see the link below: